U.S. FDA Sends Warning Letter To Ozempen.com; FDA Observed That Introduces Into Interstate Commerce Unapproved And Misbranded Semaglutide Drug Products; Requests Cease Offering Any Unapproved And Misbranded Drugs For Sale To U.S. Consumers
U.S. FDA Sends Warning Letter To Ozempen.com; FDA Observed That Introduces Into Interstate Commerce Unapproved And Misbranded Semaglutide Drug Products; Requests Cease Offering Any Unapproved And Misbranded Drugs For Sale To U.S. Consumers
美國食品藥品監督管理局給Ozempen.com發送了警告信; FDA發現其將未經批准和標籤錯誤的Semaglutide藥品引入州際商業; 要求停止向美國消費者銷售任何未經批准和標籤錯誤的藥品。
U.S. FDA Sends Warning Letter To Ozempen.com; FDA Observed That Introduces Into Interstate Commerce Unapproved And Misbranded Semaglutide Drug Products; Requests Cease Offering Any Unapproved And Misbranded Drugs For Sale To U.S. Consumers
美國食品藥品監督管理局給Ozempen.com發送了警告信; FDA發現其將未經批准和標籤錯誤的Semaglutide藥品引入州際商業; 要求停止向美國消費者銷售任何未經批准和標籤錯誤的藥品。